The newly-released data indicates that at 29 to 34 months after initial treatment, there was highly significant symptomatic improvement. There were no serious safety issues reported in individuals treated with NX-1207.
Patients in the trial who were available for follow-up were administered AUA symptom score evaluations after periods of 29 to 34 months post treatment.
The mean AUA score in patients treated with NX-1207 showed a 6.9 point greater improvement compared to controls. This reached statistical significance and exceeded results from the initial 30-day study of NX-1207.
75% of the subjects in the trial were available for follow-up. Of these, 57% of the subjects treated with NX-1207 required no further treatment for BPH symptoms, and showed a mean improvement of 7.2 points in AUA scores.
BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.